Shetty Vanaja P, Wakade Anju V, Ghate Sunil D, Pai Vivek V
The Foundation for Medical Research, 84- A, R.G. Thadani Marg, Worli, Mumbai - 400 018, India.
Lepr Rev. 2011 Sep;82(3):235-43.
Sixty two patients with relapsed leprosy seen between Jan 2004 and Dec 2009 were studied using clinical, bacteriological and histopathological parameters. The findings thus obtained were correlated to parameters such as trend and source of referral, clinical characteristics at diagnosis, treatment received, other events during or after RFT and duration between cessation of treatment and relapse.
Referrals per year have doubled since 2006. Most patients were referred by NGOs (58%), followed by Govt. hospitals (16%) and then by GPs (25%); 76% had received one of the WHO - MDT regimens including 16 treated with 24 months or more MB - MDT, 23 with 12 months MB - MDT and eight with 6 months PB - MDT. Of the remaining 14 cases, four had received DDS mono-therapy, seven had single dose of Rifampicin, Ofloxacin and Minocycline (ROM) and four Rifampicin and Ofloxacin (RO) daily for 28 days. The average incubation time of relapse, defined as duration between cessation of treatment and relapse was (SD) + 6-4 years. 59% of patients had positive slit skin smears on relapse. Relapse for the second time occurred in six BL cases including five from group 2 and one RO treated patient and 11/23 cases from group 2 conferred to BT-BB leprosy. Clinical features at diagnosis and on relapse were comparable in 47% of cases.
All leprosy patients, regardless of their type and MDT regime, carry 'risk of relapse'. A shorter treatment duration reduces the incubation time to relapse. In group 2 (treated with 12 months MB-MDT regime) 11/23 were BT-BB cases and 5/23 (21%) were relapse for the second time, which further supports our earlier documented findings and maybe the efficacy of WHO-MDT regime is poor in a small subset of patients.
对2004年1月至2009年12月期间收治的62例复发性麻风患者进行了临床、细菌学和组织病理学参数研究。将由此获得的结果与诸如转诊趋势和来源、诊断时的临床特征、接受的治疗、反应停治疗期间或之后的其他事件以及治疗停止与复发之间的持续时间等参数相关联。
自2006年以来,每年的转诊人数翻了一番。大多数患者由非政府组织转诊(58%),其次是政府医院(16%),然后是全科医生(25%);76%的患者接受了世界卫生组织多药联合化疗方案中的一种,其中16例接受了24个月或更长时间的多菌型多药联合化疗,23例接受了12个月的多菌型多药联合化疗,8例接受了6个月的少菌型多药联合化疗。其余14例中,4例接受了氨苯砜单一疗法,7例接受了利福平、氧氟沙星和米诺环素(ROM)单剂量治疗,4例接受了利福平和氧氟沙星(RO)每日治疗28天。复发的平均潜伏期定义为治疗停止与复发之间的持续时间,为(标准差)+6 - 4年。59%的患者复发时皮肤涂片阳性。6例瘤型麻风患者出现第二次复发,其中5例来自第2组,1例接受RO治疗的患者,第2组的23例中有11例转变为偏结核样型麻风。47%的病例诊断时和复发时的临床特征具有可比性。
所有麻风患者,无论其类型和多药联合化疗方案如何,都有“复发风险”。较短的治疗持续时间会缩短复发的潜伏期。在第2组(接受12个月多菌型多药联合化疗方案治疗)中,23例中有11例为偏结核样型麻风,23例中有5例(21%)第二次复发,这进一步支持了我们早期记录的结果,也许世界卫生组织多药联合化疗方案在一小部分患者中的疗效较差。